Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | SVP & Chief Scientific Officer | January 29, 2021 | February 18, 2021 |
| BriaCell Therapeutics Corp.BCTX · Entity 7454 | Director | August 01, 2022 | August 01, 2022 |
| aTYR PHARMA INCATYR · Entity 7233 | Director | May 11, 2026 | May 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date January 29, 2021 · Filed February 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.50 · Expires 2031-01-29 | Direct | 16,500 |
Reported balance
After 2021-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-29 · Grant · Acquired 16,500 · Balance 16,500 F1: The option vests in three approximately equal annual installments beginning on January 29, 2022. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 5,500 |
Reported balance
After 2021-01-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-29 · Grant · Acquired 5,500 · Balance 5,500 F2: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. F3: The RSU vests in three approximately equal annual installments beginning on January 29, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in three approximately equal annual installments beginning on January 29, 2022.
F2: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis.
F3: The RSU vests in three approximately equal annual installments beginning on January 29, 2022.
BriaCell Therapeutics Corp.
Report date August 01, 2022 · Filed August 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.74 · Expires 2026-11-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-08-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.47 · Expires 2027-01-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-08-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The Option vests quarterly for 2 years from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The Option vests quarterly for 2 years from the date of grant.
aTYR PHARMA INC
Report date May 11, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2036-05-11 | Direct | 50,000 |
Reported balance
After 2026-05-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-11 · Grant · Acquired 50,000 · Balance 50,000 F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2026 Filed May 13, 2026 20:14 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001684258-26-000003 · ownership.xml · derivative · entry 1 Gross Jane A · CIK 0001684258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-05-11 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 01, 2025 Filed May 2, 2025 21:20 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0000950170-25-062937 · ownership.xml · derivative · entry 1 Gross Jane A · CIK 0001684258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-01 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 1, 2026 or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| March 17, 2025 Filed Mar 17, 2025 23:07 UTC | aTYR PHARMA INC ATYR · Entity 7233 | PurchaseCommon Stock | 3,750 | $4.00 | $15,000.00 |
DisclosureSEC source: 0000950170-25-040600 · ownership.xml · nonDerivative · entry 1 Gross Jane A · CIK 0001684258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,750 Read SEC document |
| May 22, 2024 Filed May 23, 2024 23:27 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0000950170-24-064229 · ownership.xml · derivative · entry 1 Gross Jane A · CIK 0001684258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 22, 2025 or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:29 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001209191-23-031012 · doc4.xml · derivative · entry 1 Gross Jane A · CIK 0001684258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 17, 2024 or (ii) the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:52 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026064 · doc4.xml · derivative · entry 2 Gross Jane A · CIK 0001684258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: RSUs convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs fully vested one year from the grant date which was April 26, 2022. F3 · derivative.expiration_date: The RSUs fully vested one year from the grant date which was April 26, 2022. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:52 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionCommon stock | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-026064 · doc4.xml · nonDerivative · entry 1 Gross Jane A · CIK 0001684258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on April 26, 2022. F2 · price: RSUs convert into common stock on a one-for-one basis. Read SEC document |
| April 26, 2022 Filed Apr 28, 2022 23:46 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026089 · doc4.xml · derivative · entry 1 Gross Jane A · CIK 0001684258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs, granted pursuant to the Issuer's non-employee director compensation policy, vest in full on the earlier of (i) April 26, 2023 or (ii) the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. F2 · derivative.expiration_date: The RSUs, granted pursuant to the Issuer's non-employee director compensation policy, vest in full on the earlier of (i) April 26, 2023 or (ii) the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 00:08 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 1,428 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-21-029121 · doc4.xml · derivative · entry 1 Gross Jane A · CIK 0001684258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,428 Underlying: Common Stock · 1,428 shares Expires 2031-04-28 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) April 28, 2022 or (ii) the Issuer's 2022 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| January 29, 2021 Filed Feb 18, 2021 02:01 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-21-000142 · gross.xml · derivative · entry 2 Gross Jane A · CIK 0001684258 · SVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSU vests in three approximately equal annual installments beginning on January 29, 2022. F3 · derivative.expiration_date: The RSU vests in three approximately equal annual installments beginning on January 29, 2022. Read SEC document |
| January 29, 2021 Filed Feb 18, 2021 02:01 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $33.50 | $0.00 |
DisclosureSEC source: 0001019056-21-000142 · gross.xml · derivative · entry 1 Gross Jane A · CIK 0001684258 · SVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-01-29 F1 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on January 29, 2022. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:50 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 2,140 | Not disclosed Strike: $8.56 | Not disclosed |
DisclosureSEC source: 0001019056-20-000451 · gross.xml · derivative · entry 9 Gross Jane A · CIK 0001684258 · SVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,140 Underlying: Common Stock · 2,140 shares Expires 2030-07-26 F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F11 · derivative.exercise_date: These options will vest in three approximately equal annual installments beginning on the one year anniversary of the date of grant. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:50 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 7,784 | Not disclosed Strike: $8.56 | Not disclosed |
DisclosureSEC source: 0001019056-20-000451 · gross.xml · derivative · entry 8 Gross Jane A · CIK 0001684258 · SVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,784 Underlying: Common Stock · 7,784 shares Expires 2030-07-26 F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F10 · derivative.exercise_date: These options vest in full on the one year anniversary of the date of grant. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:50 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 4,814 | Not disclosed Strike: $21.28 | Not disclosed |
DisclosureSEC source: 0001019056-20-000451 · gross.xml · derivative · entry 7 Gross Jane A · CIK 0001684258 · SVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,814 shares Expires 2029-02-28 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F9 · derivative.exercise_date: This stock option award provides for vesting in three approximately equal annual installments beginning on February 28, 2020. Prior to July 27, 2020, all but 3,210 shares of the issuer's common stock underlying this stock option had vested. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:50 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 4,814 | Not disclosed Strike: $43.82 | Not disclosed |
DisclosureSEC source: 0001019056-20-000451 · gross.xml · derivative · entry 6 Gross Jane A · CIK 0001684258 · SVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,814 shares Expires 2028-03-09 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F8 · derivative.exercise_date: This stock option award provides for vesting in three approximately equal annual installments beginning on March 9, 2019. Prior to July 27, 2020, all but 1,605 shares of the issuer's common stock underlying this stock option had vested. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:50 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 2,407 | Not disclosed Strike: $30.10 | Not disclosed |
DisclosureSEC source: 0001019056-20-000451 · gross.xml · derivative · entry 5 Gross Jane A · CIK 0001684258 · SVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,407 shares Expires 2027-06-01 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F7 · derivative.exercise_date: This stock option award vested over three years, and the final one-third vested on June 1, 2020. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:50 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 2,407 | Not disclosed Strike: $27.44 | Not disclosed |
DisclosureSEC source: 0001019056-20-000451 · gross.xml · derivative · entry 4 Gross Jane A · CIK 0001684258 · SVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,407 shares Expires 2027-02-24 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F6 · derivative.exercise_date: This stock option award vested over three years, and the final one-third vested on February 24, 2020. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:50 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 3,908 | Not disclosed Strike: $41.58 | Not disclosed |
DisclosureSEC source: 0001019056-20-000451 · gross.xml · derivative · entry 3 Gross Jane A · CIK 0001684258 · SVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,908 shares Expires 2026-02-28 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F5 · derivative.exercise_date: This stock option award vested over three years, and the final one-third vested on March 1, 2019. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:50 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 2,779 | Not disclosed Strike: $35.70 | Not disclosed |
DisclosureSEC source: 0001019056-20-000451 · gross.xml · derivative · entry 2 Gross Jane A · CIK 0001684258 · SVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,779 shares Expires 2022-03-09 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F4 · derivative.exercise_date: This stock option award vested on March 10, 2018. This award was originally part of a grant from Emergent dated March 11, 2015, of which two-thirds were vested at the time of conversion to the issuer's equity pool. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:50 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 2,072 | Not disclosed Strike: $34.58 | Not disclosed |
DisclosureSEC source: 0001019056-20-000451 · gross.xml · derivative · entry 1 Gross Jane A · CIK 0001684258 · SVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,072 shares Expires 2021-03-10 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F2 · derivative.exercise_date: This stock option award vested on March 10, 2017. This award was originally part of a grant from Emergent BioSolutions Inc. ("Emergent") dated March 11, 2014, of which two-thirds were vested at the time of conversion to the issuer's equity pool. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:57 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 1,428 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001209191-20-027966 · doc4.xml · derivative · entry 1 Gross Jane A · CIK 0001684258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,428 Underlying: Common Stock · 1,428 shares Expires 2030-05-06 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 6, 2021 or (ii) the Issuer's 2021 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| February 18, 2020 Filed Mar 19, 2020 22:33 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 134,800 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001019056-20-000240 · gross.xml · derivative · entry 1 Gross Jane A · CIK 0001684258 · SVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,800 Underlying: Common Stock · 134,800 shares Expires 2030-02-17 F1 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on February 17, 2021. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 01:52 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 122,982 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001019056-19-000612 · gross.xml · derivative · entry 1 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,982 Underlying: Common Stock · 122,982 shares Expires 2029-10-31 F1 · derivative.exercise_date: The options vest on November 1, 2020, the one-year anniversary of the grant date. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 21:14 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 2,285 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001209191-19-040447 · doc4.xml · derivative · entry 1 Gross Jane A · CIK 0001684258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,285 Underlying: Common Stock · 2,285 shares Expires 2029-06-28 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning July 28, 2019, such that this option will be fully exercisable on June 28, 2022, subject to the recipient's continued service on the Issuer's Board of Directors. F2 · derivative.underlying_shares: The shares of Common Stock reported herein give effect to the 1-for-14 reverse stock split which became effective in accordance with the terms of the Certificate of Amendment to the Company's Restated Certificate of Incorporation filed with the Secretary of State of Delaware on June 28, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:04 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 9,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-19-000176 · gross.xml · derivative · entry 4 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,138 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. 9,140 shares of common stock underlying the RSUs vested on each of March 1, 2017 and March 1, 2018, and the remaining 9,138 shares vested on March 1, 2019. F3 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. 9,140 shares of common stock underlying the RSUs vested on each of March 1, 2017 and March 1, 2018, and the remaining 9,138 shares vested on March 1, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:04 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 2,710 | $1.57 | $4,254.70 |
DisclosureSEC source: 0001019056-19-000176 · gross.xml · nonDerivative · entry 2 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,583 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 02:04 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 9,138 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-19-000176 · gross.xml · nonDerivative · entry 1 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 02:04 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 67,400 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001019056-19-000176 · gross.xml · derivative · entry 3 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Underlying: Common Stock · 67,400 shares Expires 2029-02-28 F2 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on February 28, 2020. Read SEC document |
| March 09, 2018 Filed Mar 14, 2018 01:36 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 9,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-18-000433 · gross_4.xml · derivative · entry 4 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,138 Underlying: Common Stock · 9,728 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 10, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, each RSU was adjusted and assumed by the Issuer. The RSUs fully vested as of March 9, 2018. F3 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 10, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, each RSU was adjusted and assumed by the Issuer. The RSUs fully vested as of March 9, 2018. Read SEC document |
| March 09, 2018 Filed Mar 14, 2018 01:36 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantEmployee Stock Options (Right to Buy) · Derivative | 67,400 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001019056-18-000433 · gross_4.xml · derivative · entry 3 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,400 Underlying: Common Stock · 67,400 shares Expires 2028-03-09 F2 · derivative.exercise_date: On March 9, 2018, the reporting person was granted 67,400 stock options vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 09, 2018 Filed Mar 14, 2018 01:36 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 2,282 | $3.13 | $7,142.66 |
DisclosureSEC source: 0001019056-18-000433 · gross_4.xml · nonDerivative · entry 2 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,155 Read SEC document |
| March 09, 2018 Filed Mar 14, 2018 01:36 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 9,728 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-18-000433 · gross_4.xml · nonDerivative · entry 1 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 00:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 9,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-18-000417 · gross_4.xml · derivative · entry 2 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,866 Underlying: Common Stock · 9,140 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F2 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest as follows: 9,140 on March 1, 2017, 9,140 on March 1, 2018 and 9,138 on March 1, 2019. F2 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest as follows: 9,140 on March 1, 2017, 9,140 on March 1, 2018 and 9,138 on March 1, 2019. Read SEC document |
| March 01, 2018 Filed Mar 6, 2018 00:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 9,140 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-18-000417 · gross_4.xml · nonDerivative · entry 1 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| February 03, 2018 Filed Feb 7, 2018 00:22 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 18,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-18-000289 · gross_4.xml · derivative · entry 2 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,006 Underlying: Common Stock · 18,136 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 3, 2016, the reporting person was granted 36,271 RSUs, vesting in two equal installments on February 3, 2017 and February 3, 2018. F2 · derivative.expiration_date: On August 3, 2016, the reporting person was granted 36,271 RSUs, vesting in two equal installments on February 3, 2017 and February 3, 2018. Read SEC document |
| February 03, 2018 Filed Feb 7, 2018 00:22 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 18,136 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-18-000289 · gross_4.xml · nonDerivative · entry 1 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 19:59 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 38,093 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000648 · gross_4.xml · derivative · entry 3 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,142 Underlying: Common Stock · 38,093 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F2 · derivative.exercise_date: The RSUs were originally issued on August 3, 2016 and fully vested on August 1, 2017. F2 · derivative.expiration_date: The RSUs were originally issued on August 3, 2016 and fully vested on August 1, 2017. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 19:59 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 10,076 | $1.83 | $18,439.08 |
DisclosureSEC source: 0001019056-17-000648 · gross_4.xml · nonDerivative · entry 2 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,433 Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 19:59 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 38,093 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-17-000648 · gross_4.xml · nonDerivative · entry 1 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 01:38 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantEmployee Stock Option (right to buy) · Derivative | 33,700 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001019056-17-000544 · gross_4.xml · derivative · entry 1 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,700 Underlying: Common Stock · 33,700 shares Expires 2027-05-31 F1 · date: The option grant was approved by a committee of Aptevo Therapeutics Inc.'s board of directors on February 22, 2017, subject to stockholder approval of the Amended and Restated 2016 Stock Incentive Plan (the "Plan") under which the option was granted. Aptevo Therapeutics Inc.'s stockholders approved the Plan on May 31, 2017. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 1, 2018. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 01:06 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 14,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000290 · gross_4.xml · derivative · entry 9 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,235 Underlying: Common Stock · 14,506 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F4 · derivative.exercise_date: The RSUs were originally issued by Emergent on March 11, 2014 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs fully vested on March 10, 2017. F4 · derivative.expiration_date: The RSUs were originally issued by Emergent on March 11, 2014 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs fully vested on March 10, 2017. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 01:06 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 3,837 | $1.78 | $6,829.86 |
DisclosureSEC source: 0001019056-17-000290 · gross_4.xml · nonDerivative · entry 6 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,416 Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 01:06 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 14,506 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-17-000290 · gross_4.xml · nonDerivative · entry 5 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| March 09, 2017 Filed Mar 14, 2017 01:06 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 9,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000290 · gross_4.xml · derivative · entry 8 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,741 Underlying: Common Stock · 9,727 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were originally issued by Emergent on March 10, 2015 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs vest as follows: 9,727 on March 9, 2017 and 9,728 on March 9, 2018. F3 · derivative.expiration_date: The RSUs were originally issued by Emergent on March 10, 2015 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs vest as follows: 9,727 on March 9, 2017 and 9,728 on March 9, 2018. Read SEC document |
| March 09, 2017 Filed Mar 14, 2017 01:06 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 2,573 | $1.80 | $4,631.40 |
DisclosureSEC source: 0001019056-17-000290 · gross_4.xml · nonDerivative · entry 4 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,747 Read SEC document |
| March 09, 2017 Filed Mar 14, 2017 01:06 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 9,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-17-000290 · gross_4.xml · nonDerivative · entry 3 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| March 01, 2017 Filed Mar 14, 2017 01:06 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 9,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000290 · gross_4.xml · derivative · entry 7 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,468 Underlying: Common Stock · 9,140 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F2 · derivative.exercise_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest as follows: 9,140 on March 1, 2017, 9,140 on March 1, 2018 and 9,138 on March 1, 2019. F2 · derivative.expiration_date: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest as follows: 9,140 on March 1, 2017, 9,140 on March 1, 2018 and 9,138 on March 1, 2019. Read SEC document |
| March 01, 2017 Filed Mar 14, 2017 01:06 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 2,148 | $2.02 | $4,338.96 |
DisclosureSEC source: 0001019056-17-000290 · gross_4.xml · nonDerivative · entry 2 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,593 Read SEC document |
| March 01, 2017 Filed Mar 14, 2017 01:06 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 9,140 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-17-000290 · gross_4.xml · nonDerivative · entry 1 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
| February 24, 2017 Filed Feb 27, 2017 21:03 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 33,700 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001019056-17-000232 · gross_4.xml · derivative · entry 1 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,339 Underlying: Common Stock · 33,700 shares Expires 2027-02-24 F1 · derivative.exercise_date: The options vest in three equal annual installments beginning on February 24, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.